{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:09:36Z","timestamp":1780384176710,"version":"3.54.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bacterial ventriculitis associated with CSF shunts or drains is a life-threatening infection often caused by MDR pathogens such as Stenotrophomonas maltophilia. Cefiderocol, an IV siderophore cephalosporin approved for drug-resistant Gram-negative infections, lacks extensive clinical data supporting its use in CNS infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We describe a case of S. maltophilia ventriculitis successfully treated with cefiderocol monotherapy at a standard dose of 2\u2005g IV every 8\u2005h. Data on cefiderocol CSF drug penetration are reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cefiderocol trough plasma and CSF concentrations (Cmin) were determined at steady-state conditions, and S. maltophilia susceptibility testing was determined using Etest and disc diffusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Therapeutic drug monitoring showed sustained CSF cefiderocol concentrations. CSF cefiderocol Cmin remained 116.0- and 131.8-fold above the isolate\u2019s MIC throughout the dosing interval, with plasma-to-CSF penetration ratios of 16.6%\u201325.7%. Patient\u2019s clinical cure was achieved after 26\u2005days of therapy without adverse events or relapse at 1\u00a0year of follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data show that cefiderocol at a standard dose of 2\u2005g IV every 8\u2005h achieved sustained therapeutic concentrations in the CSF. Cefiderocol monotherapy may be an option for CNS infections with MDR Gram-negative bacteria with low MICs such as S. maltophilia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlag092","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:05:37Z","timestamp":1778760337000},"source":"Crossref","is-referenced-by-count":0,"title":["Effective cefiderocol CSF penetration for treating\n                    <i>Stenotrophomonas maltophilia<\/i>\n                    ventriculitis"],"prefix":"10.1093","volume":"8","author":[{"given":"Clara","family":"Ribera","sequence":"first","affiliation":[{"name":"Pharmacy Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Padull\u00e9s","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]},{"name":"University of Barcelona, Faculty of Pharmacy , Barcelona ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fe","family":"Tubau","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]},{"name":"Research Network for Respiratory Diseases (CIBERES-CB06\/06\/0037), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Corral","sequence":"additional","affiliation":[{"name":"Intensive Care Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nu\u00f1ez Garate","sequence":"additional","affiliation":[{"name":"Biochemistry Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Cabellos","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Infectious Diseases Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Vilalta","sequence":"additional","affiliation":[{"name":"Neurosurgical Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0817-0931","authenticated-orcid":false,"given":"Jordi","family":"C\u00e0mara","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]},{"name":"Research Network for Respiratory Diseases (CIBERES-CB06\/06\/0037), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cobo-Sacrist\u00e1n","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Abelenda-Alonso","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Infectious Diseases Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Di Paolo","sequence":"additional","affiliation":[{"name":"Intensive Care Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1882-1259","authenticated-orcid":false,"given":"Evelyn","family":"Shaw","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Infectious Diseases Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-2218","authenticated-orcid":false,"given":"Mireia","family":"Puig-Asensio","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Infectious Diseases Department, Bellvitge University Hospital-IDIBELL, L\u2019Hospitalet de Llobregat , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026060202431162000_dlag092-B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4266\/acc.2021.01151","article-title":"Nosocomial meningitis in intensive care: a 10-year retrospective study and literature review","volume":"37","author":"Valdoleiros","year":"2022","journal-title":"Acute Crit Care"},{"key":"2026060202431162000_dlag092-B2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMra0804573","article-title":"Nosocomial bacterial meningitis","volume":"362","author":"Van de Beek","year":"2010","journal-title":"N Engl J Med"},{"key":"2026060202431162000_dlag092-B3","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac040","article-title":"Clinical challenges treating Stenotrophomonas maltophilia infections: an update","volume":"4","author":"Mojica","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2026060202431162000_dlag092-B4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/jac\/dkab015","article-title":"Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections","volume":"76","author":"Parsels","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026060202431162000_dlag092-B5","author":"European Medicines Agency"},{"key":"2026060202431162000_dlag092-B6","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Mesachiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"2026060202431162000_dlag092-B7","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/jac\/dkac066","article-title":"Cerebrospinal fluid concentrations of cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis","volume":"77","author":"Luque-Paz","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026060202431162000_dlag092-B8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac391","article-title":"Clinical cure of a difficult-to-treat resistant Pseudomonas aeruginosa ventriculitis using cefiderocol: a case report and literature review","volume":"9","author":"Marcelo","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026060202431162000_dlag092-B9","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1093\/jac\/dkac248","article-title":"Plasma and cerebrospinal fluid concentrations of cefiderocol during successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis","volume":"77","author":"Kufel","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026060202431162000_dlag092-B10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/antibiotics13050453","article-title":"Role of cefiderocol in multidrug-resistant Gram-negative central nervous system infections: real life experience and state-of-the-art","volume":"13","author":"Sollima","year":"2024","journal-title":"Antibiotics (Basel)"},{"key":"2026060202431162000_dlag092-B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/phar.4632","article-title":"Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: a case report","volume":"45","author":"Finch","year":"2025","journal-title":"Pharmacotherapy"},{"key":"2026060202431162000_dlag092-B12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01022-17","article-title":"Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model","volume":"61","author":"Monogue","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 7","key":"2026060202431162000_dlag092-B13","doi-asserted-by":"publisher","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026060202431162000_dlag092-B14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1093\/cid\/ciaf071","article-title":"The effectiveness of newer beta-lactams for the treatment of antimicrobial-resistant Gram-negative meningitis","volume":"80","author":"Hsu","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026060202431162000_dlag092-B15","first-page":"1","article-title":"Antibiotic diffusion to central nervous system","volume":"31","author":"Cabrera-Maqueda","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"2026060202431162000_dlag092-B16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40262-013-0062-9","article-title":"Clinical pharmacokinetics of antibacterials in cerebrospinal fluid","volume":"52","author":"Di Paolo","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2026060202431162000_dlag092-B17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/3\/dlag092\/68446839\/dlag092.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/3\/dlag092\/68446839\/dlag092.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:43:17Z","timestamp":1780382597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag092\/8699663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag092","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,30]]},"article-number":"dlag092"}}